Logo image
Se connecter
Retour
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Article de revue   Avec comité de lecture

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Hervé Tilly, Franck Morschhauser, Laurie H Sehn, Jonathan W Friedberg, Marek Trněný, Jeff P Sharman, Charles Herbaux, John M Burke, Matthew Matasar, Shinya Rai, …
The New England journal of medicine, Vol.386(4), pp.351-363
27/01/2022
DOI: https://doi.org/10.1056/NEJMoa2115304
PMID: 34904799

Résumé

Hematology Leukemia Lymphoma Oncology Treatments in Oncology
The treatment outcome for diffuse large B-cell lymphoma has not been improved in nearly 20 years. However, the replacement of vincristine in R-CHOP with polatuzumab vedotin, an anti-CD79b antibody linked to emtansine, led to a progression-free survival benefit over R-CHOP at 2 years (76.7% vs. 70.2%), with a similar safety profile.

Indicateurs

1 Consultations de la notice

Détails

Logo image